RxDoctor Payments Data

Allan Gittman, MD

Family Medicine · Pompano Beach, FLNPI 1487640256

Payments from drug & device makers

$297in general payments, 2019–2025

Across 16 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$101
  • Amgen$73
  • Collegium Pharmaceutical, Inc.$32
  • Novo Nordisk$30
  • GSK$17
  • Forte Bio-pharma LLC$16
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$297100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)4$101
Amgen(2 entities)4$73
Collegium Pharmaceutical, Inc.2$32
Novo Nordisk2$30
GSK1$17
Forte Bio-pharma LLC1$16
Hikma Pharmaceuticals USA1$15
Orexo US, Inc.1$13

How this compares

$297 in reported general payments places this provider in the 40th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$11,206
Medicare patients
20
Services billed
79

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GilenyaFingolimod Hcl13$135,445
OxycontinOxycodone Hcl68$103,409
EliquisApixaban42$44,064
OzempicSemaglutide32$35,709
Oxycodone Hcl437$13,852
EntrestoSacubitril/Valsartan12$13,050
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl73$11,170
XareltoRivaroxaban14$10,776
Morphine Sulfate ErMorphine Sulfate251$9,935
ZubsolvBuprenorphine Hcl/Naloxone Hcl18$7,923
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen198$6,059
Morphine Sulfate55$3,021
Albuterol Sulfate HfaAlbuterol Sulfate88$2,801
Gabapentin172$1,932
Alprazolam398$1,655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$30$37,15946 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate, Buprenorphine Hcl$15$14,980144 claims
Orexo US, Inc.Zubsolv$13$7,92318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Pompano Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →